Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.61 |
| ▸ | SCN1A | P35498 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betoxycaine SCHEMBL25758 | 0.90 | CYP2D6 (0.77) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| Betoxycaine SCHEMBL6898673 | 0.85 | CYP2D6 (0.82) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL5654276 | 0.80 | CYP1A2 (0.65) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL28029759 | 0.78 | PHLPP2 (0.62) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL14304168 | 0.77 | CYP1A2 (0.70) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL10728959 | 0.77 | CYP1A2 (0.60) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL8170977 | 0.77 | CYP1A2 (0.60) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL2314260 | 0.77 | CYP1A2 (0.60) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| Proparacaine SCHEMBL20704827 | 0.77 | SCN1A (0.71) | CYP1A2SCN1AKCNH2SCN2ASCN3A | |
| SCHEMBL7156485 | 0.76 | CYP1A2 (0.61) | CYP1A2SCN1AKCNH2SCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-7790762-B2 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH HEALTH (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2217259-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Health (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1562563-B1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH HEALTH (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009052411-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7498047-B2 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1954681-A2 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | National Jewish Medical and Research Center (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1931345-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007073518-A9 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | NAT JEWISH MED & RES CENTER (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007073518-A2 | COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007024741-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1562563-A4 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH MED & RES CENTER (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1562563-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004042020-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | ABCC1, ABCC2, ABCB1 | CYP1A2 1078/4885SCN1A 3354/4885KCNH2 3952/4885 |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | ABCC1, CFTR, ABCC2 | CYP1A2 1086/4885SCN1A 3598/4885KCNH2 3856/4885 |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | CYP1A2 1075/4885SCN1A 1648/4885KCNH2 2134/4885 |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | ABCC2, CFTR, ABCC1 | CYP1A2 1237/4885SCN1A 1301/4885KCNH2 2381/4885 |
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | ABCC1, CFTR, SLC47A1 | CYP1A2 1469/4885SCN1A 2244/4885KCNH2 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.